. Even as clinically localized prostate cancer has become highly curable, the overall death toll remains high owing to recurrence of 'cured' cases and progression to hormone-refractory metastatic disease, which remains uncurable 3 . Conversely, nonspecific PSA tests result in a large number of false positives for prostate cancer, leading to a faux cancer burden and repeated biopsies 4 . More specific diagnostic modalities, prognostic indicators of progression and a better understanding of prostate cancer biology for treatment of hormone-refractory disease are high priorities in prostate cancer research.
Approximately 2.5 years ago, our group identified recurrent genomic rearrangements in prostate cancer resulting in the fusion of the 5′ untranslated end of TMPRSS2 (a prostate-specific, androgen-responsive, transmembrane serine protease gene) to ets family genes (oncogenic transcription factors) 5 . The original findings have been rapidly corroborated by several independent groups worldwide and now the focus is on the functional and clinical correlates of prostate cancer in the context of the gene fusions. Emerging experimental evidence suggests that these fusions are key molecular entities driving the development and progression of a unique class of prostate cancers, providing potential avenues for targeted therapy.
Gene fusions resulting from chromosomal rearrangements are the most prevalent form of genetic alterations known in cancers 6 and, as exemplified by the archetype gene fusion BCR-ABL1 (known as the Philadelphia chromosome) in CML 7, 8 , they can serve as ideal diagnostic markers [9] [10] [11] , provide insight into tumour biology 12 , and most importantly serve as specific therapeutic targets 13, 14 . Intriguingly, although numerous gene fusions have been described in rare haematological malignancies and even rarer bone and soft tissue sarcomas 15 , they are much rarer among epithelial cancers. Gene fusions described among epithelial cancers so far have included RET-NTRK1 fusions in papillary thyroid carcinoma, PAX8-PPARG in follicular thyroid carcinoma, MECT1 (also known as CRTC1)-MAML2 in mucoepidermoid carcinoma, TFE3-TFEB in kidney carcinomas, and BRD4-NUT (also known as C15orf55) in midline carcinomas (reviewed in Ref. 16 ; see Mitelman Database of Chromosomal Aberrations in Cancer URL in Further information). Remarkably, recurrent gene fusions have not previously been detected in the most prevalent carcinomas, including prostate, breast (with the exception of rare, secretory breast cancers), lung, gastrointestinal and gynaecological tumours 17 , despite compelling arguments that predict their occurence 15, 18, 19 . The absence of gene fusions in common solid tumours has been attributed to the technical difficulties associated with their cytogenetic analysis. Also, epithelial cancers are thought to be clonally heterogeneous, with causal chromosomal aberrations 
Gene fusion
A physical linking of two genes (typically accompanied by deletion of portions of the two partner genes) such that they come to share a common regulatory element and/or open reading frames, the latter encoding chimeric proteins, for example BCR-ABL1 or TMPRSS2-ERG.
co-habiting the tissues with clinically irrelevant ones. Although cytogenetic analyses can help identify 'physical' genomic aberrations (see Atlas of Genetics and Cytogenetics URL in Further information), recurrent gene fusions in prostate cancer were identified on the basis of gene expression data, bypassing the technical limitations of cytogenetics in solid cancers. This strategy led to the identification of recurrent gene fusions in common solid cancers, close to 50 years after the discovery of Philadelphia chromosome in 1960s.
In this Review, we appraise recent progress in the characterization of recurrent gene fusions in prostate cancer. we highlight the clinical implications of new discoveries, emerging controversies and challenges, as well as future research directions. In addition to serving as potential diagnostic and prognostic markers and therapeutic candidates for a unique class of prostate cancer, the discovery of recurrent rearrangements in prostate cancer affirms a more generalized role for similar chromosomal aberrations in other common epithelial cancers.
Discovering gene fusions with bioinformatics
Cancers are, for the most part, phenotypically and molecularly heterogeneous entities. Thus, characterization of distinct molecular classes with an overarching influence of a single gene or two is clinically and therapeutically significant. For example, in one-quarter to one-third of all breast cancer cases, amplification and overexpression of the oncogene HER2 (also known as ERBB2) defines an aggressive class that is more likely to metastasize, develop hormone resistance and respond significantly to HER2-targeted therapy. Likewise, Philadelphia chromosome-positive chronic myeloid leukaemia typifies 10% of all leukaemia cases, where the underlying aberration is a BCR-ABL1 gene fusion that becomes the focal point of diagnosis, classification, prognostication and therapy, as well as follow-up and recurrence monitoring
. other well-defined cancer classes include less than 5% of all breast cancers harbouring BRCA1 or BRCA2 mutations 20 , 6% of colon cancers with microsatellite instability or germline mutations characterizing specific clinical classes such as hereditary non-polyposis colorectal cancer or familial adenomatus polyposis 21, 22 , and 10% of nonsmall-cell lung cancers (nSCLCs) harbouring sensitizing mutations in epidermal growth factor receptor (EGFR) that respond to the EGFR-targeting drug gefitinib 23 . we initiated a systematic identification of candidate oncogenes activated by chromosomal rearrangements or high-level copy number changes on the basis of gene expression signatures using an unconventional analytical approach. Cancer gene expression data sets were queried for genes that are highly overexpressed in a subset of samples rather than focusing on those that are widely shared in all samples 5 . To identify such 'outlier' genes, we applied a data transformation algorithm, cancer outlier profile analysis (CoPA), to all of the 132 gene-expression data sets (comprising >10,000 microarray experiments from various cancers) available in oncomine [24] [25] [26] [27] (see URL in Further information), our gene expression compendium (fIG. 1) . CoPA transformation effectively compresses typical biomarker profiles characterized by a general overexpression of genes in all cancer samples, while accentuating 'outlier gene' profiles, which are characterized by general low expression with marked overexpression in a fraction of the samples. Prioritized outlier genes identified by our systematic approach included several well-known cancer genes involved in recurrent chromosomal aberrations or high-level copy number changes associated with their specific cancers. Surprisingly, two genes known to be involved in gene fusions in Ewing sarcoma 28, 29 , namely ERG (ETS-related gene) and ETV1 (ETS variant gene 1), were scored as high-ranking outliers in several independent prostate cancer profiling studies. Akin to Ewing sarcoma, where Ewing sarcoma breakpoint region 1 (EWSR1)-ERG and EWSR1-ETV1 fusion genes are mutually exclusive in different cases 28 , ERG and ETV1 overexpression were mutually exclusive in prostate cancer. This suggested that increased expression of ERG-ETV1 may be a key molecular event in a subset of prostate cancers.
Analysis of prostate cancer samples that overexpress ERG and ETV1 ('outliers') using exon-walking quantitative PCR revealed overexpression of only their 3′ regions, suggestive of a genetic rearrangement (fIG. 1) . This lead us to characterize the 5′ ends of ERG and ETV1 transcripts using a 5′ RnA ligase-mediated rapid amplification of cDnA ends (RACE) methodology (fIG. 1) . we discovered that the 5′ ends of ERG and ETV1 are replaced with the 5′ untranslated region of TMPRSS2 (21q22.2) in the outlier cases 5 . Fusion transcripts were confirmed by quantitative PCR, and rearrangments at the genomic loci were then assessed in multiple samples by fluorescence in situ hybridization (FISH) on tissue microarrays (fIG. 1) . FISH demonstrated that a majority of prostate cancer samples harbour these aberrations. It bears noting that the
At a glance
• Approximately 50% of prostate cancers from serum prostate-specific antigen (PSA)-screened cohorts harbour recurrent gene fusions.
• The gene fusions in prostate cancer are characterized by 5′ genomic regulatory elements, most commonly controlled by androgen, fused to members of the Ets family of transcription factors.
• TMPRSS2-ERG is the most common gene fusion, present in about half of all localized prostate cancers analysed. TMPRSS2 also fuses to other Ets family genes such as ETV1, ETV4 and ETV5 in a small percentage of prostate cancers.
• ETV1, ETV4 and ETV5 have additional 5′ fusion partners that differ in their prostate specificity and response to androgen.
• Many Ets gene fusion transcript variants have been identified with different 5′ and 3′ partner sequences, probably with prognostic and/or diagnostic implications.
• Prostate cancers harbouring TMPRSS2-ERG gene fusion display characteristic morphological features of prostate cancers, such as macronucleoli and intraductal tumour spread as well as rare blue-tinged mucin, cribriform growth pattern and signet-ring cell.
• ERG overexpression imparts invasiveness to prostate cells in vitro and induces plasminogen activation and matrix metalloproteinase pathways.
• Ets gene fusion-positive and Ets gene fusion-negative prostate cancers have distinct chromosomal aberrations, expression signatures, morphological features and clinical outcomes, suggesting that they are fundamentally different classes of prostate cancer.
• Sensitive and specific diagnostic tests and targeted therapeutics will affect the detection and management of Ets-positive prostate cancer. 38 . Recently, CoPA has been used to identify genomic alterations associated with the nFκB pathway in multiple myeloma 39 , supporting the applicability of this methodology for identifying candidates for chromosomal aberration. This gene expression-based methodology effectively overcomes the barriers to cytogenetic identification of recurrent chromosomal aberrations associated with solid cancers.
Prostatic intraepithelial neoplasia (PIN
Diversity and frequency of gene fusions TMPRSS2-ERG gene fusions have been reported in approximately 50% of over 1,500 clinically localized prostate cancer samples analysed in over two dozen reports published thus far (TABLe 1) , reflecting the prevalence of such fusions in PSA-screened patient cohorts, with a lower frequency (15%) reported for a population-based cohort 40 . overall, early-and mid-stage localized prostate cancers and hormone-refractory metastatic cancers display TMPRSS2-ERG rearrangements in 50% or more cases, whereas high-grade prostatic intraepithelial neoplasia (HGPIn) appears to have a lower frequency of the gene fusions [41] [42] [43] [44] [45] (TABLe 1) . It bears noting that gene fusions
Box 1 | Gene fusions and cancer
Gene fusions are the most common class of somatic mutations associated with cancer 6 . These may involve the regulatory elements of one gene (often tissue-specific) aberrantly apposed to a proto-oncogene, for example, immunoglobulin and T-cell receptor regulatory regions fused to the MYC oncogene in B and T cell malignancies, respectively 111 . Alternatively, coding regions of two genes are juxtaposed, resulting in a chimeric protein with a new or altered activity, for example, the BCR-ABL1 gene fusion in chronic myeloid leukaemia (CML) 12, 111 and a subset of acute lymphocytic leukaemia 112, 113 .
Bcr-aBL1 paradigm
The BCR-ABL1 gene fusion on the Philadelphia chromosome (aberrant chromosome 22), discovered by Nowell and Hungerford in 1961 (Refs 10, 114) , results from a translocation of the proto-oncogene ABL1 from chromosome 9 to the BCR gene on chromosome 22. The fusion gene encodes a fusion protein, BCR-ABL1, in CML 11, 12 .
BCR-ABL1 is a diagnostic marker for CML. Detection of BCR-ABL1 fusion transcript in peripheral blood is used to confirm CML diagnosis, and to monitor cytogenetic remission and residual disease 115 .
BCR-ABL1 fusion gene has many molecular variants.
A wide variety of fusion variants of BCR-ABL1 are known, as a result of alternative breakpoint regions in BCR and in ABL1. Depending on the location of breakpoint regions, the BCR-ABL1 protein may be 210 kDa (MBcr), 190 kDa (mBcr) or 230kDa (µBcr). Different fusions have been associated with different disease phenotypes 54 .
BCR-ABL1 is pathognomonic for CML.
The BCR-ABL1 fusion protein has tyrosine kinase activity 116 , which is essential for the initiation, maintenance and progression of CML 7 . Transgenic BCR-ABL1 mice display CML-like myeloproliferative disorders [117] [118] [119] . Transgenic BCR-ABL1 expression in haematopoietic stem cells induces chronic-phase CML in mice 117, 120 .
BCR-ABL1 is a specific therapeutic target. Imatinib, a small-molecule inhibitor of ABL1 tyrosine kinase activity, is used as the standard treatment for chronic-phase CML [121] [122] [123] .
Gene fusions in carcinoma: the missing link
Whereas leukaemias and lymphomas and bone and soft tissue sarcomas, which together represent only 10% of all human cancers, account for more than 80% of all known gene fusions, common epithelial cancers, which account for 80% of cancer-related deaths, account for only about 10% of recurrent gene fusions 15, 19 . This paradox has been challenged by the recent discoveries of gene fusions in prostate and lung cancers. Nature Reviews | Cancer involving other Ets family members, primarily ETV1 but also including ETV4 and ETV5, together probably constitute less than 10% of prostate cancer samples. Considering the annual incidence (220,000 cases) of prostate cancer in the United States alone, the number of patients with Ets gene fusions probably surpasses the number of patients with BCR-ABL1 (~7,000 patients per year) and several bone and soft tissue sarcomas with individual incidences ranging from a few dozen to a few hundred per year 1, 15 . whereas high-throughput FISH assays using tissue microarray sections have been useful in screening large numbers of samples to determine the prevalence of recurrent gene fusions in prostate cancer, the characterization of Figure 1 | cytological and molecular techniques used in gene fusion studies. a, b | Cancer outlier profile analysis (COPA; described in the main text) was applied to microarray data available in Oncomine, and the top 'outlier' genes formed our primary candidates to test for potential genomic rearrangements using cytogenetic and molecular techniques. c | The downstream workflow begins with quantitative real-time PCR specific to exons from all parts of the gene (exon-walk PCR), whereby a sharply divergent expression pattern from different parts of the gene suggests that a part of the gene may be split or rearranged. d | Fusion partners of candidate split genes are identified by cloning the beginning and end of the candidate transcript using rapid amplification of cDNA ends (RACE). 5′ RACE is used to identify the 5′ fusion partner, and involves ligating an RNA adaptor sequence to the test RNA and carrying out reverse transcription PCR using RNA adaptor-specific forward primer and candidate gene-specific reverse primer (located close to the split exon). The RACE PCR products are cloned and sequenced to confirm the identity of fusion genes. e | Fusionspecific reverse transcription PCR is used to confirm the presence of fusion transcript. f | Finally, the chromosomal rearrangements involved in the gene fusion are characterized by fluorescence in situ hybridization (FISH) on interphase nuclei. FISH analysis involves hybridization of fluorescently labelled DNA probes corresponding to the candidate target sequences. As it allows visualization of specific regions of the chromosome based on DNA sequence, it is the method of choice to investigate the genomic rearrangements such as insertion, deletion and translocation that can split or fuse genes. In the 'split probe' or 'break-apart' assay strategy, two fluorescent probes (for example, green and red) are hybridized to sequences less than 1 Mb apart, so that in the normal interphase nucleus they appear co-localized. If a genetic rearrangement involves the region spanned by the two probes, the signals are separated and appear distinct (translocation), or a single colour signal is seen and the other signal is lost (deletion). In the alternative 'fusion probe' strategy, two probes are localized far apart on the chromosome or on two separate chromosomes. Two pairs of separate signals are seen in the normal diploid nucleus and in the event of a chromosomal rearrangement leading to gene fusion the two signals are co-localized. Both these techniques have been used in the gene fusion studies, often in combination. 52 , and unpublished work from other groups suggests that there are distinct phenotypical effects produced by different isoforms. Lapointe et al. have described two isoforms of TMPRSS2 that are involved in fusion with ERG: the reference sequence TMPRSS2 (exon 1), involved in about 50% of the fusions, and an alternative TMPRSS2 isoform, mapping 4 kb upstream of the reference sequence, found in 10% of the fusions. Approximately 44% of the samples reportedly expressed both the variants 48 . Early efforts to chart the molecular variants have led one group to use nested reverse transcription PCR to characterize as many as 14 fusion variants 42 and another group to characterize 8 (Ref. 52) , with many common variants identified. Although the clinical significance of these variants is undefined, some TMPRSS2-ERG fusion variants have been associated with prognostic outcomes. For example, wang et al. 52 observed that TMPRSS2 exon 2 fused with ERG exon 4 is associated with aggressive disease, and the fusion transcript with the first in-frame ATG codon present in ERG exon 3 was associated with seminal vesicle invasion (which is correlated with poor outcome). Further, other isoforms that highly express fusion mRnAs were also associated with early PSA recurrence.
BCR-ABL1 has well-characterized breakpoint clusters in both the genes that determine the nature of fusion genes Clinical, histological and molecular features Similarly to BCR-ABL1-positive leukaemias 7, 54 , colon cancers with microsatellite instability 55, 56 or breast cancers with BRCA mutations 57, 58 , Ets gene fusions in prostate cancer are associated with specific morphological features and prognoses, as well as specific molecular signatures. A particularly interesting picture is emerging in multifocal prostate cancers, where different tumour foci in a patient sample have different gene 59 . Samples which harboured three or more of these features were almost always (93%) fusion-positive and only 24% of fusion-positive samples did not display any of these morphological features 59 . Tu et al. also noted a significantly higher frequency of TMPRSS2-Ets gene fusions in mucin-positive carcinomas than mucinnegative tumours 60 . Larger studies may help establish further the phenotypic associations of the gene fusions (and their variants). A molecular connection between the gene fusions and specific morphological features will also require follow-up studies.
Prognostic association. TMPRSS2-ERG has been frequently but not unequivocally associated with more aggressive prostate cancers and a poorer prognosis. TMPRSS2 gene rearrangement has been variously associated with high pathological stage 61 and higher rate of recurrence 62 in independent cohorts of surgically treated localized prostate cancer cases, and the presence of gene fusion has been scored as the single most important prognostic factor 62, 63 . In a FISH-based analysis of 445 cancer cases, not having an ERG fusion was found to be a good prognostic factor (90% survival at 8 years) compared with cancers with duplication of TMPRSS2-ERG in combination with deletion of 5′-ERG (2+Edel), which exhibited poor cause-specific survival (25% survival at 8 years) 64 . This novel category of '2+Edel' status was found to be independent of other prognostic factors including Gleason score and serum levels of PSA. In the assessment of gene fusion status in a populationbased 'watchful waiting' cohort of men with localized prostate cancer (mostly comprising good or uncertain prognoses), tumours from just 15% of the patients were found to harbour TMPRSS2-ERG fusion. Remarkably, this fusion-positive subset was significantly associated with prostate cancer-specific death 40 . In another study involving primary prostate cancers and hormone-naive lymph node metastases, a significant association was observed between TMPRSS2-ERG rearranged tumours and higher tumour stage, as well as the presence of metastatic disease involving pelvic lymph nodes 43 . Similarly, Rajput et al. observed more frequent TMPRSS2-ERG fusions in moderate to poorly differentiated tumours as compared with well-differentiated tumours 49 . In a cohort of patients treated for clinically localized prostate cancer, nami et al. observed that TMPRSS2-ERG fusionpositive subgroup of patients had a significantly higher risk of recurrence (58.4% at 5 years) than fusion-negative patients (8.1%) 63 . However, many studies have reported an absence of such clinical correlation between the fusions and prognosis. In a report preceding the discovery of gene fusions, Clearly, more studies, with larger patient cohorts, would help resolve specific prognostic association of the gene fusions.
Multifocal prostate cancer.
Localized prostate cancer is typically multifocal with different foci displaying histological and molecular heterogeneity 67 . when the status of gene rearrangements in 93 tumour foci from 43 radical prostatectomy resections were analysed, 70% of the cases were found to be rearranged at the TMPRSS2 locus, a higher proportion than accounted for by TMPRSS2-ERG fusions seen in 55% of the cases 68 . our study showed that a small percentage of prostate cancers cases might harbour uncharacterized fusion partners driven by the upstream regulatory elements of TMPRSS2 (Refs 61, 68) . Further, attesting to the heterogeneity of multifocal cancers, 70% of the cases showed divergent gene rearrangements in the different foci 68 . In another study of TMPRSS2-ERG fusions in multifocal prostate cancers, Barry et 43 . Together, these observations strongly suggest that metastatic cancer arises through clonal expansion of malignant cells from a unique primary focus of dissemination, which argues for a careful assessment of different tumour foci of a patient for an accurate prognostication 71 (fIG. 3) .
Other clinical associations. Although gene fusions are prima facie acquired somatic mutations, we have observed samples from hereditary prostate cancer patients to be three times more likely to harbour ERG rearrangements than those from sporadic prostate cancers patients (R. Mehra & A.M.C., unpublished observations). Similar familial associations have also been reported with respect to gene fusion-rich myeloproliferative disorders 72 . our observations could have important clinical implications for the 5-10% of hereditary (as well as 10-20% of familial) prostate cancer patients 73 .
Interestingly, our preliminary observations do not suggest any racial differences in the prevalence of the gene fusions (R. Mehra and A.M.C., unpublished observations). Any future studies dealing with these important assessments would need to factor in the multifocal heterogeneity of the rearrangements, as well as include broader Ets family gene rearrangement screens. Another area of clinical interest would be the assessment of rearrangement status in response to salvage radiotherapy that could facilitate the identification of patients at risk for recurrence.
Molecular aberrations associated with gene fusions.
To elucidate the role of Ets gene fusions in prostate cancer biology (fIG. 4) , attempts have been made to define gene expression signatures of Ets-overexpressing prostate cancers. A meta-analysis of multiple expression data from 410 human prostate tissue samples (178 normal and 232 tumours and metastases) was performed to identify genes correlated with ERG overexpression 47 . A strong association was made with high expression of HDAC1 and (presumably, consequently) low expression of its target genes. In the same study, an increased expression of wnt-associated pathways and downregulation of TnF and cell death pathways was also noted. Gene expression profiling of TMPRSS2-ERG-positive samples led Setlur et al. to define an 87-gene signature enriched for oestrogen receptor signalling pathway genes, associated with the gene fusion-positive prostate cancer tissues 74 . Follow-up functional studies corroborated the regulation of TMPRSS2-ERG expression by oestrogenic compounds in a non-androgen-responsive prostate cancer cell line harbouring the fusion. Increased expression of oestrogen receptor α (also known as ESR1) has been associated with prostate cancer progression, metastasis and androgen-resistant phenotype 75 . Taken together, these observations suggest an attractive new therapeutic approach for metastatic prostate cancers that fail androgen ablation therapy (discussed in more detail below).
As Ets gene fusions appear to account for 50-60% of all prostate cancers, non-Ets fusion cancers might constitute a clinically relevant group as well. we carried out a meta-analysis of three independent gene expression profiling studies [76] [77] [78] for comparison of Ets fusion-positive prostate cancers with non-Ets cancers. Importantly, Etspositive and Ets-negative tumours had distinct expression signatures that were maintained across studies and platforms. Using a molecular concepts-based analysis (Molecular Concepts Map 24 ), we observed a relative underexpression of genes on chromosomal region 6q21 (for example, FOXO3A and CCNC) in non-Ets prostate cancers 77 . In a subsequent array-comparative genomic hybridization analysis from our group, we noted a loss of 6q21 in more than 45% of non-Ets samples 79 . Recently, Lapointe et al. described a deletion at a nearby locus, 6q15, in non-Ets prostate cancer samples 80 . Together, these results suggest that Ets-positive and Ets-negative tumours may be fundamentally different types of prostate cancer, driven by distinct genetic aberrations whose effects can be seen in expression signatures. 44 . The latter report also indicated that fusion-positive HGPIn is almost always present in close proximity to fusion-positive cancer tissue. A recent 33, 77, 87 and comprise genes involved in increased protein synthesis, cell adhesion and invasion, including urokinase plasminogen activator (PLAU) and several matrix metalloproteases. Preceding genetic lesions, including the loss of a tumour suppressor such as PTEN, probably drive the development of prostatic intraepithelial neoplasia, whereas subsequent Ets gene-mediated molecular alterations lead to the development of invasive prostate carcinogenesis. DHT, dihydrotestosterone; GO, gene ontology; HPRD, human protein reference database; MMP, matrix metalloproteinase. study by Clark et al. reports HGPIn, as well as some foci resembling low-grade PIn, closely associated with fusion-positive prostate cancer that harbour ERG rearrangements, in as many as six out of nine prostate cancer samples analysed 70 . Together, these observations strongly suggest that the Ets gene rearrangements might be early events in prostate carcinogenesis.
PIN studies. TMPRSS2-ERG

Functional studies of Ets gene fusions
Functional characterization of the role of Ets gene fusions in prostate cancer has primarily focused on assessment of prostate specificity and androgen responsiveness of the fusion genes and the mechanistic role of fusion genes in carcinogenesis. As TMPRSS2 is prostate-specific and strongly induced by androgen [81] [82] [83] , we tested whether the TMPRSS2-ERG fusion gene is androgen-regulated as well. Androgen treatment induced ERG expression in prostate cancer cell line vCaP harbouring TMPRSS2-ERG fusion, but not in LnCaP cells, which are androgenresponsive but do not have this fusion 5 . Likewise, there was no induction of ERG or TMPRSS2-ERG expression in the androgen-insensitive nCI-H660 prostate cancer cell line carrying the TMPRSS2-ERG fusion 84 . Similarly, Hermans et al. found ERG expression restricted to the androgensensitive human prostate cancer xenografts carrying the TMPRSS2-ERG fusion, but not in androgen-insensitive samples nor in the samples without the fusion 46 . Although only TMPRSS2 has been reported as a 5′ fusion partner of ERG, additional 5′ partners have been identified for ETV1, ETV4 and ETV5. These 5′ partners include TMPRSS2, SLC45A3, HERV-K_22q11.23, C15orf21, CANT1 and KLK2, which are prostate-specific, and HNRPA2B1, which has a ubiquitous housekeeping expression. with respect to androgen regulation, TMPRSS2, SLC45A3, HERV-K_22q11.23, CANT1 and KLK2 contribute androgen-inducible sequences, whereas C15orf21 is repressed by androgen treatment and HNRPA2B1 is insensitive to androgens. As androgen ablation therapy is central to advanced prostate cancer management, the divergent androgen responsiveness driving the fusion genes could affect response to therapy and disease progression. This may provide important clues into the biology of hormone-insensitive samples as well.
The upstream regulatory elements of fusion partners dictate prostate-specific, androgen-responsive expression of the Ets genes, and an obvious next question is whether these gene fusions are carcinogenic in the prostate. This aspect has been investigated by our group, as well as others, and the results, though not definitive, are compelling.
To recapitulate the biological effects of aberrant overexpression of ETV1 in the prostate, truncated ETV1 was ectopically overexpressed in prostate epithelial cell lines RwPE and PrEC. Surprisingly, we found it did not cause cell transformation and had no effect on cell proliferation or anchorage-independent growth; instead, it made the epithelial cells invasive through Matrigel assays 33 . In a complementary observation, LnCaP cells lost their invasiveness when ETV1 expression was knocked down 33, 85 . Consistent with these phenotypical observations, the gene expression signature of ETV1-overexpresssing RwPE cells shows an enrichment of molecular concepts (biologically related genes) involved in invasion 33 .
To investigate the effects of the gene fusions in vivo, we generated transgenic mice overexpressing ETV1 in prostate epithelium (using a prostate-specific, androgenregulated, probasin (Pb) promoter 86 ). Six out of eight (75%) transgenic mice developed mouse PIn (mPIn), which was variably present in all three prostatic lobes (anterior, ventral and dorsolateral), by 12-14 weeks of age. Consistent with our in vitro observations, none of the mPIn foci developed into tumours, which strongly suggests that additional genetic lesions and/or environmental factors are required for the development of carcinoma. virtually identical observations were made in ERG overexpression studies in vitro as well as in transgenic Pb-ERG mice by two independent groups 87, 88 , and in ETV5 overexpression studies in vitro 89 . That transgenic Pb-ERG and Pb-ETV1 mice do not develop frank carcinoma is consistent with clinical observations in human prostate cancer development and progression. Comprehensive FISH analysis showed no ERG rearrangements in benign prostate glands, ~20% of PIn lesions (but only intermingling with cancer foci that harboured similar ERG rearrangements), ~50% of localized prostate cancers and ~30% of metastatic prostate cancers 44 . Thus, preceding genetic lesions probably function to deregulate cellular proliferation resulting in PIn, whereas Ets fusions drive the transition to carcinoma. As metastatic foci from a single case are homogeneous in regard to Ets status, Ets fusions clearly occur before metastasis. we 33, 87 and others 90 have speculated that loss of tumour suppressors such as PTEN or NKX3-1 may precede and cooperate with Ets gene fusions to drive cancer development; compound transgenic mice recapitulating these lesions will probably be an ideal model of human prostate cancer.
Diagnostic, prognostic and predictive implications
The application of serum measurement of PSA in prostate cancer diagnosis, prognosis and disease follow-up has had a dramatic effect on prostate cancer management by providing a simple and sensitive primary screening modality to diagnose prostate cancers at a curable stage (reviewed in Ref. 4) . However, the PSA test exhibits poor specificity, and is often increased in benign conditions such as prostatitis and benign prostatic hyperplasia 91, 92 . 94 . As prostate tumour cells are also shed in the urine, PCR-based detection of fusion transcripts from urine sediments could provide a non-invasive adjunct to diagnose this class of prostate cancer. we reported sensitive and specific detection of TMPRSS2-ERG fusion transcript from the urine sediments of prostate cancer patients 95 , and analysed the fusion transcript in combination with other putative prostate cancer biomarkers in urine sediments using quantitative PCR 96 . In the latter discovery study, multiplexed detection of GOLPH2 (also known as GoLM1), SPINK1, PCA3 and TMPRSS2-ERG fusion transcripts outperformed serum PSA or PCA3 alone in detecting prostate cancer. Combined detection of TMPRSS2-ERG and PCA3 transcripts in urine was reported to provide improved sensitivity of detection of prostate cancer in another study 97 . Future refinement of these tests might lead to a clinical supplement to serum PSA for detecting Ets-positive prostate cancer.
As discussed above, the interfocal heterogeneity of prostate cancer gene fusions predicates assessment of multiple-needle biopsies 68 .
with the continual refinement of clinical association studies, we expect that identification of specific gene fusions will assist in a molecular classification of prostate cancers. For example, as specific fusion subtypes (such as EDel) are correlated with poorer outcome, patients harbouring these events could be considered for more aggressive treatment modalities. Importantly, as indicated by multiple regulatory partners of ETV1 (Ref. 33) , it is surmised that this information may eventually become integral to therapeutic decision making.
Therapeutic implications
Androgen signalling is pivotal to prostate cancer development and survival. Androgen ablation therapy continues to be a core treatment modality since the pioneering application of castration and oestrogen administration by Charles Huggins in early 1940s 3, 98, 99 , which was followed by use of LHRH (also known as GnRH1) agonists by Andrew Schally 100 , and more recently replaced by various androgen receptor blockers 101 , such as cyproterone 102 and cyproterone acetate 103 , followed by non-steroidal anti-androgens like flutamide 104 , bicalutamide and nilutamide 101 . Unfortunately, although androgen ablation provides considerable palliative relief for most patients, it is almost never completely curative, either as a monotherapy or in combined androgen blockade modalities, and eventually most recurrent tumours progress to hormone-independent disease 105, 106 . TMPRSS2-ERG fusion-bearing tumours have been associated with aggressive tumours with lethal phenotype, so it follows that targeting ERG activity in fusionpositive samples might offer novel therapeutic avenues for prostate cancer. Discovery of oestrogen signalling pathways induced in TMPRSS2-ERG-positive nonandrogen-responsive cases might be significant in this respect. Efforts are also underway to identify small molecule inhibitors of ERG activity, as well as downstream targets of ERG protein, that could provide additional therapeutic targets.
Future directions
Genomic rearrangements creating 'gene fusions' arguably represent the most common mutation class in human cancers, even though until recently they have been largely characterized in rare haematological and soft tissue malignancies 6 . In this respect, the presence of similar gene fusions in cancers of epithelial origin is remarkable for having eluded discovery till recently. Identification of recurrent gene fusions in prostate cancer by the 'noncytogenetic' approach of gene expression analysis followed by characterization of 'outlier' genes represents a novel technique, albeit one of many possible, to explore solid cancers for similar genomic aberrations. The recent report of the presence of EML4-ALK fusion transcript in 6.7% (5 out of 75) of nSCLC patients, revealed by functional screening of the cancer tissue transcriptome (cDnA expression library) 107 , and the discovery of ALK and ROS1 fusion proteins in nSCLC through an outlier analysis of the phosphoproteome of cancer tissues and cell lines 108 , represent other successful approaches. Genome-wide search for 'fusion transcripts' by nextgeneration sequencing approaches 109, 110 followed by high-throughput tissue microarray-FISH are likely to be used for future gene fusion explorations in other common carcinomas. we envision a wider prevalence of gene fusions in prostate cancer, possibly involving other regulatory elements and non-Ets genes that are yet to be discovered (fIG. 5 ).
An understanding of the diverse regulatory 'on/off switches' driving oncogene expression in prostate cancer tissues might lead to clarification of the molecular heterogeneity of multifocal prostate cancer in tandem with the clonally homogenous nature of disseminated foci of metastatic tumours. Recurrent gene fusions appear to be correlated with prostate cancer development and progression, and more studies with larger patient cohorts should identify specific clinical correlates. Continued studies on the relationship between gene fusions, androgen responsiveness and hormonerefractory metastatic disease is crucial as the varying androgen responsiveness of different regulatory elements might drive markedly different responses with androgen deprivation therapy. Considering the research summarized in this Review, we propose a molecular classification of prostate cancers -Ets fusion-positive and Ets fusion-negative -that will probably serve to guide future diagnostic, prognostic and therapeutic advances in prostate cancer.
